Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
AstraZeneca
Medtronic
McKesson
Baxter

Last Updated: January 28, 2022

Volunteer for clinical trials for ADVIL DUAL ACTION WITH ACETAMINOPHEN at ClinicalTrialExchange

DrugPatentWatch Database Preview

ADVIL DUAL ACTION WITH ACETAMINOPHEN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Advil Dual Action With Acetaminophen, and when can generic versions of Advil Dual Action With Acetaminophen launch?

Advil Dual Action With Acetaminophen is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ADVIL DUAL ACTION WITH ACETAMINOPHEN is acetaminophen; ibuprofen. There are sixty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the acetaminophen; ibuprofen profile page.

Summary for ADVIL DUAL ACTION WITH ACETAMINOPHEN
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Clinical Trials: 76
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ADVIL DUAL ACTION WITH ACETAMINOPHEN?ADVIL DUAL ACTION WITH ACETAMINOPHEN excipients list
DailyMed Link:ADVIL DUAL ACTION WITH ACETAMINOPHEN at DailyMed
Drug patent expirations by year for ADVIL DUAL ACTION WITH ACETAMINOPHEN
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ADVIL DUAL ACTION WITH ACETAMINOPHEN
Generic Entry Date for ADVIL DUAL ACTION WITH ACETAMINOPHEN*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ADVIL DUAL ACTION WITH ACETAMINOPHEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 2
Baylor College of MedicinePhase 1
University of Texas Southwestern Medical CenterPhase 1

See all ADVIL DUAL ACTION WITH ACETAMINOPHEN clinical trials

Pharmacology for ADVIL DUAL ACTION WITH ACETAMINOPHEN

US Patents and Regulatory Information for ADVIL DUAL ACTION WITH ACETAMINOPHEN

ADVIL DUAL ACTION WITH ACETAMINOPHEN is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ADVIL DUAL ACTION WITH ACETAMINOPHEN is ⤷  Sign up for a Free Trial.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting ADVIL DUAL ACTION WITH ACETAMINOPHEN

NEW PRODUCT
Exclusivity Expiration: ⤷  Sign up for a Free Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ADVIL DUAL ACTION WITH ACETAMINOPHEN acetaminophen; ibuprofen TABLET;ORAL 211733-001 Feb 28, 2020 OTC Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.